Rewcastle continued, "The fact that the Enox technology can be applied to any polymer medical device including silicone, and that the medical system is massively burdened by the cost of treating infections, yields a truly unique opportunity. Leading a company that has the potential of benefiting patients, physicians and hospitals, while significantly reducing the overall cost of healthcare, is a challenge I welcome with confidence and pride."About Enox Biopharma, Inc.Enox Biopharma, Inc. is an emerging biotechnology company with proprietary technology that embeds nitric oxide (NO) into polymeric medical devices. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. Enox's technology is applicable to any indwelling polymeric medical device including, but not limited to, catheters, endotracheal tubes, tympanostomy tubes and cosmetic implants. With the current CMS non-coverage of nosocomial infections the financial burden of infections has shifted to hospitals who are desperately seeking ways to reduce infection rates. By utilizing NO, part of the human body's innate immune system, Enox Biopharma is improving existing medical devices by making them uniquely antimicrobial. Reducing infection rates without antibiotics benefits patients, physicians, hospitals and decreases the overall cost of health care.
Forward Looking Information
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on management's good faith views and expectations when made. Forward-looking statements are inherently subject to known and unknown risks and uncertainties which, in the case of the company, include raising adequate capital to co
|SOURCE Enox Biopharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved